Studies reveal the therapeutic mechanism of action for levetiracetam to prevent the production of Aβ and, consequently, downstream irreversible damage.

Accent Therapeutics launched a Phase I/II clinical trial last year to begin testing a small molecule inhibitor of KIF18A in ovarian cancers.

Products released at this year's meeting covered a broad range of applications from sustainable labware to protein assays to instruments.

Unchained Labs launched Stuntman during the SLAS meeting in Boston: an automation platform that combines native, natural-language AI with flexible hardware.